BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

China’s 2024 National Reimbursement Drug List Expands Access to Cutting-Edge Therapies

The National Healthcare Security Administration of China has unveiled the 2024 National Reimbursement Drug List (NRDL), incorporating several pioneering th...

November 29, 2024 | News

Duality Biologics and Adcendo Expand Collaboration to Strengthen ADC Cancer Therapy Pipeline

Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate therap...

November 26, 2024 | News

Akeso's Penpulimab and Anlotinib Combo Accepted by NMPA for First-Line Advanced Liver Cancer Treatment

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accep...

November 25, 2024 | News

Boehringer Ingelheim Introduces VETMEDIN® Solution: A Liquid Option for Managing Canine Heart Failure

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime Previous studies have shown t...

November 25, 2024 | News

NVIDIA’s BioNeMo Framework Unites Pharma, TechBio, and AI Leaders to Advance Drug Discovery

Argonne National Laboratory, Flagship Pioneering, Terray, Weights & Biases and Dozens More Organizations Among Contributors Advancing Biomolecular Scie...

November 22, 2024 | News

Lepu Biopharma and DP Technology Achieve Milestone in ADC Drug Development Through AI-Powered Collaboration

This partnership has effectively integrated DP's ADC Linker-Payload design platform with Lepu's ADC technology development platform, capitalizing on t...

November 22, 2024 | News

Converge Bio Secures $5.5M Seed Funding to Transform Drug Discovery with Generative AI

Converge Bio, a generative AI platform for accelerated drug discovery and development, announced it has raised $5.5 million in seed funding, ...

November 21, 2024 | News

Eisai Launches Rozebalamin® in Japan, Offering New Hope for ALS Patients

Eisai Co., Ltd. announced that the amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection25 mg” (mecobalamin) has ...

November 21, 2024 | News

GBI Biomanufacturing Expands Services with Automated Sterile Fill-Finish Capabilities

GBI Biomanufacturing (GBI), one of the world's longest serving contract development and manufacturing organizations (CDMO), is pleased to announce the expa...

November 21, 2024 | News

Ractigen Therapeutics Receives FDA Orphan Drug Designation for RAG-21, a Novel siRNA Therapy for FUS-ALS

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, announced that the U.S. Food and Drug Administ...

November 20, 2024 | News

Everest Medicines' NEFECON® Gains Full Approval in South Korea for IgA Nephropathy Treatment

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

November 19, 2024 | News

Acepodia Secures FDA IND Clearance for ACE1831, Pioneering Gamma Delta T Cell Therapy in Autoimmune Disease

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T...

November 18, 2024 | News

Ascentage Pharma’s Lisaftoclax NDA Accepted for Priority Review in China: A Potential First for Bcl-2 Inhibitors

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unm...

November 18, 2024 | News

Mabwell's Nectin-4 Targeting ADC Secures IND Approval for Clinical Trials in Perioperative Urothelial Carcinoma and Advanced Solid Tumors

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its novel Nectin-4 targeting ADC (R&D code: 9MW...

November 15, 2024 | News

Stay Connected